Indegene Limited (NSE:INDGN) Annual Results: Here's What Analysts Are Forecasting For This Year

Indegene Limited (NSE:INDGN) shareholders are probably feeling a little disappointed, since its shares fell 6.3% to ₹532 in the week after its latest full-year results. Indegene reported in line with analyst predictions, delivering revenues of ₹28b and statutory earnings per share of ₹17.02, suggesting the business is executing well and in line with its plan. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Taking into account the latest results, the current consensus from Indegene's five analysts is for revenues of ₹31.8b in 2026. This would reflect a decent 12% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to climb 15% to ₹19.63. Before this earnings report, the analysts had been forecasting revenues of ₹32.2b and earnings per share (EPS) of ₹20.35 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.

See our latest analysis for Indegene

It might be a surprise to learn that the consensus price target was broadly unchanged at ₹611, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Indegene, with the most bullish analyst valuing it at ₹700 and the most bearish at ₹495 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Indegene's revenue growth is expected to slow, with the forecast 12% annualised growth rate until the end of 2026 being well below the historical 21% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 15% per year. Factoring in the forecast slowdown in growth, it seems obvious that Indegene is also expected to grow slower than other industry participants.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Indegene. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Indegene. Long-term earnings power is much more important than next year's profits. We have forecasts for Indegene going out to 2028, and you can see them free on our platform here.

We also provide an overview of the Indegene Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.